NCT06715072View on ClinicalTrials.gov

Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma

Not yet recruitingOBSERVATIONAL

Enrollment

70

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Unresectable Liver Cancer

All Listed Sponsors

lead

Yao Xie

OTHER